Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.

被引：6
|
作者：
Smyth, Elizabeth Catherine
Turner, Nicholas C.
Pearson, Alex
Peckitt, Clare
Chau, Ian
Watkins, David J.
Starling, Naureen
Rao, Sheela
Gillbanks, Angela
Kilgour, Elaine
Sumpter, Katherine Anne
Smith, Neil R.
Cutts, Ros
Rooney, Claire
Thomas, Anne L.
Ajaz, Mazhar A.
Chua, Sue
Brown, Gina
Popat, Sanjay
Cunningham, David
机构：
[1] Royal Marsden, London, England
[2] Inst Canc Res, London SW3 6JB, England
[3] Royal Marsden Hosp, London SW3 6JJ, England
[4] AstraZeneca Oncol Innovat Med, Macclesfield, Cheshire, England
[5] Northern Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England
[6] Leicester Royal Infirm, Leicester, Leics, England
[7] Royal Surrey Cty Hosp, Guildford, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.154
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
154
引用
收藏
页数：1
相关论文
共 50 条
  • [21] TARGET TRIAL: A PHASE I/II OPEN-LABEL MULTICENTER STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFICACY OF AZD4547 IN PATIENTS WITH RELAPSED/REFRACTORY FGFR FUSION POSITIVE GLIOMA
    Picca, Alberto
    Di Stefano, Anna Luisa
    Savatovsky, Julien
    Ducray, Francois
    Chinot, Olivier
    Moyal, Elisabeth Cohen-Jonathan
    Augereau, Paule
    Schmitt, Yohann
    Lerond, Julie
    Rousseaux, Nabila
    Fardeau, Christine
    Mokhtari, Karima
    Bielle, Franck
    Meyronet, David
    Iavarone, Antonio
    Sanson, Marc
    NEURO-ONCOLOGY, 2023, 25
  • [22] A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study
    Bang, Yung-Jue
    Van Cutsem, Eric
    Mansoor, Wasat
    Petty, Russell D.
    Chao, Yee
    Cunningham, David
    Ferry, David
    Landers, Donal
    Stockman, Paul
    Smith, Neil R.
    Geh, Catherine
    Kilgour, Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] A phase II clinical trial of the single agent oral FGF receptor inhibitor AZD4547 as second of third line therapy in malignant pleural mesothelioma: final results of the FRAME study
    Lam, Wei-Sen
    Nowak, Anna K.
    Chen, Fred
    Muruganandan, Sanjeevan
    Arunachalam, Sukyana
    Loong, Melvin
    Millward, Michael
    Murray, Kevin
    Read, Cathy
    Creaney, Jenette
    Lee, Gary Y. C.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 84 - 84
  • [24] A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data.
    Paik, Paul K.
    Shen, Ronglai
    Ferry, David
    Soria, Jean-Charles
    Mathewson, Alastair
    Kilgour, Elaine
    Landers, Donal
    Frewer, Paul
    Brooks, Nigel
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non-Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models (vol 18, pg 6658, 2012)
    Zhang, J.
    Zhang, L.
    Su, X.
    Li, M.
    Xie, L.
    Malchers, F.
    Fan, S.
    Yin, X.
    Xu, Y.
    Liu, K.
    Dong, Z.
    Zhu, G.
    Qian, Z.
    Tang, L.
    Schoettle, J.
    Zhan, P.
    Ji, Q.
    Kilgour, E.
    Smith, P. D.
    Brooks, A. N.
    Thomas, R. K.
    Gavine, P. R.
    CLINICAL CANCER RESEARCH, 2013, 19 (13) : 3714 - 3714
  • [26] A phase II study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results.
    Jin, Min
    Yang, Shengli
    Liu, Junli
    Zhang, Jieying
    Zhao, Lei
    Yu, Dandan
    Lin, Zhenyu
    Li, Pindong
    Wang, Jing
    Xue, Jun
    Ma, Hong
    Hu, Jianli
    Zhang, Tao
    Liu, Hongli
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 407 - 407
  • [27] RADICAL trial: A phase lb/IIa study to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients progressing on these aromatase inhibitors (AIs).
    Seckl, Michael
    Badman, Philip David
    Liu, Xinxue
    MacPherson, Lain R.
    Zubairi, Ishtiaq Husain
    Baird, Richard D.
    Garcia-Corbacho, Javier
    Crest, Nicola
    Plummer, Elizabeth R.
    Armstrong, Anne Caroline
    Allerton, Rozenn
    Landers, Donal
    Nicholas, Hanna
    McLellan, Lynda
    Lim, Adrian K.
    Coombes, Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic rental cell cancer: Phase I results.
    Angevin, E.
    Lin, C.
    Pande, A. U.
    Lopez, J. A.
    Gschwend, J.
    Harzstark, A. L.
    Shi, M.
    Anak, O.
    Escudier, B. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Phase II study with S-1 in patients with advanced gastric cancer:: Preliminary results.
    Chollet, P
    Schöffski, P
    Bruntsch, U
    Schellens, J
    Pavlidis, N
    Droz, J
    Favre, R
    Oliveira, J
    Volk, J
    Vermorken, J
    Wanders, J
    de Boer, R
    Fumoleau, P
    CLINICAL CANCER RESEARCH, 2000, 6 : 4552S - 4552S
  • [30] Phase II trial of AZD1775 in combination with carboplatin and paclitaxel in stage IV squamous cell lung cancer (sqNSCLC): Preliminary results.
    Gray, Jhanelle Elaine
    Tanvetyanon, Tawee
    Creelan, Ben C.
    Antonia, Scott Joseph
    Haura, Eric B.
    Williams, Charles C.
    Yaseen, Raheel
    Schell, Michael J.
    Godin, Robert
    Rix, Uwe
    Monteiro, Alvaro
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345